Why the study?
Does intracerebroventricular losartan attenuate the elevated metabolic rate induced by DOCA-salt treatment in mice?
Population
Male C57BL/6J mice (6 to 8 weeks old)
Design
Preclinical
Follow-up
21 days
Authors
Loading...
Central AT1 blockade may mitigate metabolic effects in salt-sensitive models independently of BP; leaves open translation to human hypertension therapies.
Does intracerebroventricular losartan attenuate the elevated metabolic rate induced by DOCA-salt treatment in mice?
Angiotensinergic signaling within the brain mediates the metabolic consequences of DOCA-salt treatment independently of blood pressure alterations.
Grobe et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: